Pacira Pharmaceuticals share price logo

Pacira Pharmaceuticals

NASDAQ: PCRX

Small Cap

$25.76

-0.07

(-0.27%)

as on

Pacira Pharmaceuticals Stock Performance

as on August 29, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $25.55
    $26.05
    downward going graph

    0.82%

    Downside

    1.13%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $18.80
    $27.66
    downward going graph

    27.02%

    Downside

    7.38%

    Upside

    downward going graph

Pacira Pharmaceuticals share price movements today

Previous Close
$25.83
Open
$25.99
Volume
468.4K
Market Cap
$1.0B
Day's Low - High
$25.55 - $26.05
52 Week Low - High
$18.80 - $27.66

Pacira Pharmaceuticals Historical Returns

1 Month Return
-3.66 %
3 Month Return
+ 9.08 %
1 Year Return
-3.8 %
3 Year Return
-29.17 %
5 Year Return
-56.52 %

Pacira Pharmaceuticals Stock Fundamentals & Key Indicators

Check Pacira Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.0B

EPS (TTM)

2.8834

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.30%

PE Ratio (TTM)

74

Industry PE ratio

1.6784

PEG Ratio

11.2121

EBITDA

124.0M

Revenue (TTM)

746.2M

Profit Margin

1.96%

Return On Equity TTM

2.05%

Pacira Pharmaceuticals Stock Valuation

Track how Pacira Pharmaceuticals P/E has moved over time to understand its valuation trends.

Pacira Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (5.36x)

September 30, 2024

Industry (1.68x)

August 28, 2026

Today (74.00x)

August 28, 2026

Highest (23.06x)

June 30, 2022

LowHigh

Today’s Price to Earnings Ratio: 74.00x

Pacira Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Pacira Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$1.0B-56.52%741.96%NA
BUY$22.6B150.1%16.5886.14%NA
HOLD$19.2B17.54%-46.4434.83%2.87%
BUY$44.4BNA20.7614.55%121.78%
BUY$31.9B-63.19%12.4770.87%2.76%

Stock Returns calculator for Pacira Pharmaceuticals Stock including INR - Dollar returns

The Pacira Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Pacira Pharmaceuticals investment value today

Current value as on today

₹1,03,781

Returns

₹3,781

(+3.78%)

Returns from Pacira Pharmaceuticals Stock

-₹4,060 (-4.06%)

Dollar Impact

₹7,841 (+7.84%)

Analyst Recommendation on Pacira Pharmaceuticals Stock

Based on 6 analysts

BUY

50.00%

Buy

33.33%

Hold

16.67%

Sell

Based on 6 analysts, 50% of analysts recommend a 'BUY' rating for Pacira Pharmaceuticals. Average target price of $30

Pacira Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Pacira Pharmaceuticals.

What analysts predicted

14.13%UPSIDE

Target Price

$30

Current Price

$25.76

Analyzed by

6 Analysts

Target

$30.00

Pacira Pharmaceuticals target price $30, a slight upside of 14.13% compared to current price of $25.76. According to 6 analysts rating.

Indian Investors' Interest in Pacira Pharmaceuticals Stock

Search interest for Pacira Pharmaceuticals Stock has increased by 114% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:114% versus previous 30 day period

Pacira Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
167
178
168
187
168
181
179
196
177
192
Gross Profit
119
133
129
147
134
140
145
156
140
148
Operating Income
13
28
-139
24
1
8
6
3
4
4
EBITDA
34
58
-114
50
33
29
34
25
29
25
Interest Expense
3
3
4
3
4
4
3
3
3
3
Depreciation
18
18
20
21
21
27
21
21
21
21
Income Before Tax
13
36
-138
25
8
-1
9
0
4
2
Income Tax Expense
4
17
4
9
3
2
4
-1
2
-2
Net Income
8
18
-143
16
4
-4
5
1
2
4
Net Profit Margin
5.37%
10.61%
-85.11%
8.57%
2.85%
-2.68%
3.03%
0.83%
1.64%
2.42%

Pacira Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
276
286
337
421
429
541
666
674
700
726
Gross Profit
166
198
250
314
312
401
467
490
530
576
Operating Income
-32
-24
15
10
46
89
60
87
-73
33
EBITDA
-17
-10
33
30
63
113
140
154
29
122
Interest Expense
7
18
21
23
25
28
35
17
16
14
Depreciation
-
13
13
19
19
13
91
87
78
91
Income Before Tax
-37
-42
0
-10
20
56
13
61
-63
16
Income Tax Expense
0
0
0
0
-125
14
-2
19
36
9
Net Income
-37
-42
0
-11
145
41
15
41
-99
7
Net Profit Margin
-13.73%
-14.87%
-0.14%
-2.62%
33.87%
7.75%
2.39%
6.22%
-14.20%
0.97%

Pacira Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
18
-143
16
4
-4
5
1
2
4
Operating Cash Flow
53
53
33
35
12
60
43
25
57
Investing Cash Flow
-15
-52
0
-25
62
43
19
19
11
Financing Cash Flow
24
-2
-1
-2
-57
-257
-51
-59
-7
Change in Cash
63
-1
30
6
16
-152
10
-14
61

Pacira Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-42
0
-11
145
41
15
41
-99
7
Operating Cash Flow
17
48
70
77
125
145
154
189
151
Investing Cash Flow
-223
20
-128
-277
-20
-225
77
-83
99
Financing Cash Flow
224
8
3
222
380
-401
-183
17
-369
Change in Cash
18
78
-54
21
485
-481
49
123
-118

Mutual Funds that own Pacira Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Pacira Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
8.025696%
3199194
DFA INVESTMENT DIMENSIONS GROUP INC
2.833476%
1129477
IMPAX FUNDS SERIES TRUST I
1.881564%
750027
Fidelity Salem Street Trust
1.152797%
459527
Fidelity Concord Street Trust
1.100274%
438590

Global Institutional Holdings in Pacira Pharmaceuticals

Funds
Holdings
iShares
11.49%
Vanguard
9.37%
SPDR
3.02%
Dimensional
2.09%
Avantis
2.06%

Pacira Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 30 June

    Tue, 05:00 PM

    -

    Pacira announces divestiture of iovera° to Zimmer Biomet for up to $140 million, enhancing its biopharmaceutical focus.

Insights on Pacira Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 1.63M → 4.65M (in $), with an average increase of 40.6% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, PCRX stock has moved up by 4.4%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 177.37M → 192.39M (in $), with an average increase of 7.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, United Therapeutics Corporation Common Stock has given 69.1% return, outperforming this stock by 72.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 125.6% return, outperforming this stock by 153.1%

About Pacira Pharmaceuticals

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
OrganisationPacira Pharmaceuticals
Headquarters2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Frank D. Lee
E-voting on sharesClick here to vote

Key Management of Pacira Pharmaceuticals

Name

Title

Mr. Brendan P. Teehan

Chief Commercial Officer

Mr. Anthony Molloy III, Esq.

Chief Legal & Compliance Officer

Mr. Christopher C. Young

Chief Manufacturing Officer

Ms. Lauren Bullaro Riker

Principal Accounting Officer & Senior VP of Finance

Ms. Susan Mesco

Head of Investor Relations

Ms. Krys Corbett Esq.

Chief Business Officer

Mr. Frank D. Lee

CEO & Director

Mr. Shawn M. Cross

Chief Financial Officer

Ms. Kristen Williams Esq., J.D.

Chief Administrative Officer & Secretary

Dr. Jonathan Slonin M.D.

Chief Medical Officer

FAQs

What is Pacira Pharmaceuticals share price today?

Pacira Pharmaceuticals share price today is $25.76 as on at the close of the market. Pacira Pharmaceuticals share today touched a day high of $26.05 and a low of $25.55.

What is the 52 week high and 52 week low for Pacira Pharmaceuticals share?

Pacira Pharmaceuticals share touched a 52 week high of $27.66 on and a 52 week low of $18.80 on . Pacira Pharmaceuticals stock price today i.e. is closed at $25.76,which is 6.87% down from its 52 week high and 37.02% up from its 52 week low.

What is Pacira Pharmaceuticals's market capitalisation today?

Pacira Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Pacira Pharmaceuticals Stock (PCRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Pacira Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Pacira Pharmaceuticals Shares that will get you 0.0582 shares as per Pacira Pharmaceuticals share price of $25.76 per share as on August 29, 2026 at 8:46 am IST.

What is the minimum amount required to buy Pacira Pharmaceuticals Stock (PCRX) from India?

Indian investors can start investing in Pacira Pharmaceuticals (PCRX) shares with as little as ₹95.38 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.80 in Pacira Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Pacira Pharmaceuticals share’s latest price of $25.76 as on August 29, 2026 at 8:46 am IST, you will get 0.3882 shares of Pacira Pharmaceuticals. Learn more about fractional shares .

What are the returns that Pacira Pharmaceuticals has given to Indian investors in the last 5 years?

Pacira Pharmaceuticals stock has given -56.52% share price returns and 30.19% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?